A Research Guide for
Stroke Prevention & Recovery

If the stroke is ischemic (a clot), two emergency treatments can reopen the blocked artery and dramatically improve recovery — but both work only within a limited time, which is why getting to a stroke-capable hospital fast matters so much. Understanding them helps families act decisively and ask the right questions in the emergency room.

Clot-busting drugs (thrombolysis). A medication — tenecteplase (newly FDA-approved for stroke in 2025) or the older alteplase — is given through an IV to dissolve the clot. It must be started within about 4.5 hours of when symptoms began (or were last known normal), and the sooner the better: the benefit shrinks with every passing minute. Before it is given, the team does a CT scan to make sure the stroke is not a bleed, because a clot-buster would be dangerous in a hemorrhagic stroke. For strokes with an unknown start time (such as waking up with symptoms), special MRI scans can sometimes still identify people who will benefit.

Clot retrieval (thrombectomy). For larger strokes caused by a blockage in a major artery, a specialist threads a thin catheter from an artery (usually in the groin or wrist) up to the brain and physically pulls the clot out. This is one of the most effective treatments in all of medicine for the right patient, and the window has expanded — with the help of advanced brain imaging, selected patients can benefit up to 24 hours after onset. Not every hospital can perform it, which is why patients are sometimes transferred to a comprehensive stroke center.

The practical takeaway: these treatments are time-critical and hospital-dependent. Call emergency services immediately rather than driving yourself, note the time symptoms started, and let the paramedics route you to the most appropriate stroke center — decisions made in the first hour shape the rest of a person's life.

Ischemic stroke (~85% of cases) is a blockage — a clot stops blood flow. Treatment involves thinning the blood and breaking up clots.

Hemorrhagic stroke (~15%) is a bleed — a vessel ruptures. It divides into intracerebral hemorrhage (ICH, bleeding into brain tissue) and subarachnoid hemorrhage (SAH, bleeding around the brain, often from an aneurysm). Treatment requires controlling the bleed and avoiding blood thinners initially.

The distinction is established immediately by CT or MRI and flips the logic of treatment.

• The wrong drug class is dangerous. Antiplatelet therapy alone for someone with AFib leaves them under-protected; anticoagulation for someone with a recent large hemorrhagic stroke can be catastrophic.
• The workup is not optional. If your stroke was called “cryptogenic,” ask whether you have had prolonged rhythm monitoring — paroxysmal AFib is frequently missed on a single ECG.
• TIA counts. A transient ischemic attack is a warning shot, not a false alarm. It carries high short-term stroke risk and triggers the same urgent workup.
• Young stroke is different. In adults under 50, dissection, PFO, hypercoagulable states, and substance use are proportionally more common.

What makes stroke unusual among serious diseases is how preventable it is — up to 80–90% of strokes are linked to risk factors you can measure and change, often decades in advance. The most powerful thing most people can do is to know, and act on, a small set of numbers.

Blood pressure is by far the most important. High blood pressure is the single largest contributor to stroke, it usually causes no symptoms, and treating it is one of the most effective preventive actions in all of medicine. Know your blood pressure, and if it is high, treat it to target (generally below 130/80 for most people at risk). Heart rhythm matters because atrial fibrillation — an irregular heartbeat that is often silent — can throw clots to the brain; it can be found with a pulse check, an ECG, or increasingly a smartwatch, and when found it is treated with anticoagulants that cut stroke risk dramatically. Cholesterol (especially LDL) and blood sugar round out the core panel, both treatable and both silent.

Beyond the numbers, four lifestyle factors carry most of the remaining risk: not smoking, regular physical activity, a Mediterranean-style diet, and healthy weight and sleep. The AHA frames these together as “Life's Essential 8.” The encouraging reality is that these factors interact — improving several at once compounds the benefit — and that it is never too late: lowering blood pressure, quitting smoking, and treating atrial fibrillation reduce risk even in people who have already had one stroke. Ask your clinician which of these numbers you know, which you don't, and what your personal targets should be.

The 2024 guideline gives the Mediterranean diet a Class 1B recommendation. PREDIMED showed a ~42% relative reduction in stroke. The MIND diet (designed specifically for brain health) showed slower cognitive decline in stroke survivors over 5.9 years.

Build the plate:

• Half: vegetables (leafy greens daily, berries ≥2x/week)
• Quarter: lean protein (fish ≥1x/week; poultry, beans, lentils)
• Quarter: whole grains (oats, brown rice, quinoa)
• Dress with: extra-virgin olive oil; nuts daily
• Limit: processed meat, sugar drinks, fried food; sodium <2,300 mg/day (<1,500 if hypertensive)

Salt substitution: Switching to 75% NaCl / 25% KCl reduced stroke by ~14% in the SSaSS trial (n=20,995). Caution in kidney disease or with potassium-sparing diuretics.

• Aerobic: ≥150 min/week moderate (brisk walking, cycling, swimming) OR ≥75 min/week vigorous. Spread across ≥4–5 days. Raises BDNF (meta-analysis SMD ~0.84).
• Resistance training: ≥2 days/week, 8–10 exercises, 8–12 reps each.
• Balance/flexibility: Tai chi reduces falls by ~45% and lowers BP. Especially important for adults ≥65.
• Break up sedentary time: Stand or stretch every 30–45 min; total daily sitting <8 hours.

Practical start: If currently sedentary, begin with two 10-minute walks daily, five days a week — that already meets 150 min/week.

• Aspirin for primary prevention is no longer routine (ASPREE, ARRIVE, ASCEND). Reserved for selected high-risk adults after individualized discussion.
• Colchicine: A 2024 meta-analysis of 6 RCTs (14,934 patients) found colchicine reduced ischemic stroke by 27% (RR 0.73). However, the CONVINCE trial (2024, 3,154 patients with prior stroke/TIA) did not meet its primary endpoint, raising questions about the consistency of the benefit specifically in secondary stroke prevention. Accumulating evidence overall, but not yet Class 1 for stroke — discuss with your stroke team.
• PFO closure: Three landmark trials (CLOSE, RESPECT-extended, REDUCE) showed PFO closure + antiplatelet was superior for cryptogenic stroke with PFO, especially in patients <60 with moderate-to-large shunts.
• Icosapent ethyl (REDUCE-IT): In statin-treated patients with elevated triglycerides, 4 g/day reduced stroke specifically by 28%.
• CYP2C19 genotyping (CHANCE-2): ~30% carry loss-of-function variants that impair clopidogrel. Ask about genotyping if prescribed clopidogrel, especially if of Asian, African, or Hispanic ancestry.

Women-specific risks: Preeclampsia history, premature menopause, migraine with aura combined with estrogen-containing contraceptives and smoking.

The detection story has two halves: the long, quiet decades in which stroke risk can be found and lowered, and the sudden moment a stroke strikes, when recognition is measured in minutes. Both matter, but the second is where lives are saved or lost in real time. The simplest tool for recognizing a stroke as it happens is FAST: Face drooping, Arm weakness, Speech difficulty, Time to call emergency services. A newer version, BE-FAST, adds Balance (sudden loss of balance or coordination) and Eyes (sudden vision loss or double vision), because those are the symptoms of posterior (back-of-brain) strokes that plain FAST can miss.

The reason speed matters so much is biological: during an ischemic stroke, the brain loses an estimated 1.9 million neurons every minute the artery stays blocked. The treatments that reopen arteries work only within hours, and their benefit fades steadily with delay. Every minute saved getting to treatment translates into brain tissue — and function — preserved.

Two practical rules follow. First, call emergency services immediately rather than waiting to see if symptoms pass or driving to the hospital yourself — ambulances can alert the stroke team in advance and route you to the right center. Second, note the time the symptoms started (or when the person was last seen normal), because that single piece of information determines which treatments are possible. Even if symptoms disappear — which may mean a TIA, or “mini-stroke” — seek emergency care the same day, because a TIA is a serious warning that a larger stroke may be imminent and is highly preventable with prompt treatment.

The typical first-time stroke patient has had measurable, treatable risk factors for 10 to 30 years before the event. The disease that causes most strokes — atherosclerosis, atrial fibrillation, chronic hypertension — builds silently over decades. Routine medical care detects it easily. Here is the lead time each major risk factor offers:

Compare this to waiting for the stroke to happen: the median first-stroke patient arrives at the emergency department having lost millions of neurons, often with disability that even intensive rehabilitation cannot fully reverse. The treatment window for clot-busting therapy is 4.5 hours; for mechanical thrombectomy, up to 24 hours in selected patients. After that, what is lost is largely lost.

The combined effect of treating multiple risk factors is not just additive — it is multiplicative. A person who achieves blood pressure control, takes a statin, manages their glucose, stays physically active, and treats atrial fibrillation if present can reduce their lifetime stroke risk by an estimated 80–90% compared to someone who does nothing.

Concrete benefits of early detection:

• Blood pressure treatment starting in your 40s prevents the vascular damage that leads to strokes in your 60s and 70s. Every year of good control compounds.
• Catching atrial fibrillation — even if asymptomatic, found incidentally on a smartwatch or routine ECG — and starting anticoagulation prevents the most devastating cardioembolic strokes, which tend to be the largest and most disabling.
• A TIA is a second chance. ~15% of strokes are preceded by a TIA. Recognizing the temporary symptoms (face drooping, arm weakness, speech difficulty that resolves) and getting to a stroke center within hours triggers a workup that can prevent the full stroke that would otherwise follow in days to weeks.
• Lifestyle changes accumulate. Mediterranean diet, regular exercise, weight management, and smoking cessation are detectable in vascular health within months and add up over years to profoundly different vascular aging.

Most stroke is not genetic in the classical sense — it is driven by modifiable risk factors. But a few genetic conditions merit attention:

• CADASIL (NOTCH3 mutations): A hereditary small-vessel disease causing recurrent strokes, typically starting in the 30s–50s. Family members can be tested. Early diagnosis allows vascular risk factor optimization. Thrombolysis decisions are individualized — it is not absolutely contraindicated in CADASIL, but bleeding risk is weighed case-by-case with the stroke team.
• Sickle cell disease: Dramatically elevated stroke risk, especially in children. Transcranial Doppler screening and chronic transfusion therapy can prevent most childhood strokes — a genuine early-detection success story.
• Thrombophilias (Factor V Leiden, Protein C/S deficiency): Increase venous clotting risk and are relevant in young stroke patients, especially with PFO. Testing is appropriate in unexplained stroke under age 50.
• Familial hypercholesterolemia: Severely elevated LDL from birth. Early statin treatment prevents premature vascular disease including stroke. Family cascade screening is recommended when one member is identified.

If you have had a stroke under age 50 with no clear cause, or if multiple family members have had strokes, ask your stroke neurologist about genetic evaluation.

Pregnancy changes the body in ways that temporarily raise stroke risk. Blood clots more easily (a protection against bleeding at delivery that also slightly raises clot risk), blood volume and pressure on blood vessels rise, and certain pregnancy conditions add further risk. The risk is highest in the third trimester and, especially, in the first six weeks after giving birth. The most important pregnancy-specific cause is preeclampsia and eclampsia — a condition of high blood pressure in pregnancy that can lead to seizures and to both clot-type and bleeding strokes. Other causes include clots in the brain's draining veins (cerebral venous thrombosis) and a reversible spasm of brain arteries that can occur after delivery.

A sudden, severe headache — the “worst headache of your life” — during pregnancy or after delivery should never be brushed off; it can signal bleeding or a vein clot in the brain and warrants emergency evaluation. The same is true of the usual stroke warning signs (face drooping, arm weakness, speech trouble, sudden vision or balance loss), as well as new severe high blood pressure, vision changes (spots, blurring), severe swelling, or a seizure — which can be signs of preeclampsia. When in doubt, seek emergency care: these symptoms are evaluated the same urgent way as any stroke, and pregnancy does not prevent doctors from using clot-dissolving drugs or clot-retrieval procedures when they are genuinely needed.

If blood thinners are needed during pregnancy, injectable low-molecular-weight heparin is preferred because it does not cross to the baby; warfarin is generally avoided (it can harm the developing baby), and the newer oral anticoagulants (DOACs) are avoided in pregnancy and breastfeeding. Low-dose aspirin is considered safe and is actually recommended during pregnancy for women at high risk of preeclampsia. Some common stroke-prevention medicines — certain blood-pressure drugs (ACE inhibitors and ARBs) and statins — are stopped in pregnancy, and your team will substitute safer options. Most of these medicines have breastfeeding-compatible choices, so do not stop anything on your own — ask your team to build a plan.

If you have had a pregnancy-related stroke, or preeclampsia, it raises your long-term risk of stroke and heart disease later in life, so ongoing attention to blood pressure and the other prevention basics matters. It also affects planning for future pregnancies, where low-dose aspirin and close monitoring are often recommended. These are conversations to have with both a neurologist and a high-risk pregnancy (maternal-fetal medicine) specialist.

Mobile stroke units — ambulances with CT scanners — are endorsed in the 2026 AHA/ASA guideline where available. Telestroke networks extend stroke expertise to rural and underserved hospitals via real-time video: a remote stroke neurologist reviews imaging, examines the patient on camera, and guides the local team through thrombolysis decisions. If you live in a rural area, find out whether your nearest hospital participates in a telestroke network — it can mean the difference between receiving time-sensitive treatment and being transferred hours away. Know which comprehensive stroke center serves your region before you need it.

• Stroke-specific experience: Ask how many stroke patients the program treats and whether therapists hold neurologic specialization (NCS-certified).
• CARF accreditation for the stroke specialty program is a meaningful quality signal.
• Therapy dose actually delivered: Ask how many minutes per discipline per day — not the maximum allowed.
• The full team: PT, OT, speech-language pathology, physiatrist, rehabilitation nursing, neuropsychology, social work.
• Technology: Body-weight-supported gait training, functional electrical stimulation, and tracked outcomes (FIM scores).
• Caregiver training and discharge planning starting on day one.

The first days after a stroke are disorienting for patients and families alike, and knowing the general shape of what happens makes it less frightening. The initial priority is stabilization and preventing a second stroke: the team confirms the type of stroke on imaging, controls blood pressure, starts the right blood-thinning or other prevention medicine once it is safe, and watches closely for early complications. For larger strokes there is also vigilance for brain swelling, which tends to peak in the first few days. Much of this happens in a stroke unit or intensive care setting with frequent neurological checks, which can feel relentless but is how problems are caught early.

Two things often surprise families. First, a great deal of early care is about preventing problems rather than treating the stroke itself — swallowing is checked before the patient eats or drinks (to prevent pneumonia), measures are taken against leg clots, and mood and thinking are screened alongside physical function. Second, gentle rehabilitation usually begins within a day or two, but deliberately at moderate intensity: pushing too hard too early can backfire, so the careful, graded approach is intentional, not a lack of urgency.

This is also the window to get organized for what follows. Ask the team what kind of stroke it was and why (the cause shapes everything afterward), what the prevention plan is, and what rehabilitation setting is being planned for after discharge — inpatient rehab, a skilled facility, or home with outpatient therapy. Designating one family member to track information and ask questions, and beginning to understand the medications, makes the transition out of the hospital far smoother.

The 2026 AHA/ASA Guideline (Prabhakaran et al.) extends the thrombolysis window to 24 hours in selected patients, confirms tenecteplase as a thrombolytic option (single IV bolus vs 1-hour infusion, lower cost) — tenecteplase (TNKase) was FDA-approved for acute ischemic stroke in 2025, the first new stroke clot-busting drug approved in decades, so it is now a standard option alongside alteplase, not experimental — broadens thrombectomy eligibility, and discourages two formerly common practices — intensive blood-pressure lowering and tight glucose control after reperfusion.

The extended thrombectomy window builds on the landmark DAWN and DEFUSE 3 trials, which demonstrated that mechanical clot retrieval can be effective up to 16–24 hours after stroke onset in patients with a large-vessel occlusion who still have salvageable brain tissue on advanced imaging. These trials fundamentally changed stroke care by showing that the old “time is everything” rule has important exceptions — what matters most is whether viable brain tissue remains, assessed by CT perfusion or MRI. If you or a family member arrives at a hospital beyond the traditional window, ask whether perfusion imaging has been done to check for eligibility.

DOAC timing after cardioembolic stroke (ELAN trial): Early initiation (within 48 h for mild, day 6–7 for moderate, day 12–14 for severe) was non-inferior to later start. The 1-3-6-12 day heuristic is now supported by trial data.

• BP: First 24–72 h, permissive hypertension preserves penumbra. After 24–72 h, lower toward <130/80. For ICH: SBP <140 mmHg within 1 hour.
• Lipids: High-intensity statin immediately. Target LDL <70 mg/dL. Add ezetimibe or PCSK9i if not at goal.
• Glucose: Treat generally <180 mg/dL acutely. Intensive glucose control to 80–130 mg/dL is NOT recommended.
• Dysphagia screen before any oral intake — aspiration pneumonia is a leading early mortality cause.
• DVT prophylaxis: Sequential compression devices plus low-dose LMWH when safe.
• Seizure prophylaxis NOT routine after ischemic stroke (AHA Class III: No Benefit).

The AVERT trial showed frequency matters more than duration in the very early phase. Get up briefly and often, not once for a long time. A 2024 meta-analysis of 14 RCTs (3,039 patients) confirmed very early rehab within 48 hours improved daily living with no increase in adverse events.

• Position the affected arm with shoulder support to prevent subluxation
• Splinting and range-of-motion exercises to prevent contractures
• Sit-to-stand attempts; weight-shifting; standing at tilt table
• Functional electrical stimulation (FES) to activate paretic muscles
• Early speech therapy for aphasia using Melodic Intonation Therapy and CILT principles
• Hundreds of repetitions per session are achievable and matter

Mood screening within 2 weeks: PHQ-9 (depression) and GAD-7 (anxiety); repeat every 2–4 weeks for 6 months. MoCA detects post-stroke cognitive impairment far better than MMSE (70% vs 26%).

• Dose: 2–3 hours/day, 5 days/week; 300–600 task-specific repetitions/day
• Specificity: Practice the actual activities you want back (buttoning, reaching, walking on uneven surfaces) — not abstract drills
• Variability: Change tasks, increase difficulty as ability grows
• Benchmark: The Queen Square programme delivered 90 hours over 3 weeks to chronic patients and produced clinically meaningful gains that continued improving at 6-month follow-up

CIMT restrains the less-affected arm while intensively training the affected limb. A meta-analysis of 34 RCTs confirmed CIMT superior to conventional therapy for arm motor function (SMD 0.36). A network meta-analysis ranked CIMT with trunk restraint at 4–6 hours/day as the most effective upper-limb intervention. Telerehab-delivered CIMT shows comparable effect sizes, making it accessible from home.

A single session of high-intensity aerobic exercise raises circulating BDNF by ~2.5 ng/mL, creating a temporary plasticity window. Motor training performed within ~60 minutes after exercise gets amplified.

Protocol: 20–40 minutes moderate aerobic exercise (treadmill, recumbent bike, arm ergometer) at 60–70% max HR, immediately followed by 30–60 minutes of task-specific training, 3–5 days/week.

• Mirror therapy: A mirror reflects the moving unaffected limb so the patient sees “normal” movement on the affected side. Costs essentially nothing and can be done at home.
• VR-based mirror therapy: Meta-analysis of 5 RCTs showed significant FMA-UE improvement (SMD ~0.81).
• Robotics: 2025 meta-analysis of 12 RCTs found robot-assisted lower-limb training improved motor function, walking, and balance.
• Home VR: Nintendo Switch, Xbox, Meta Quest extend therapy dose affordably. Patients doing clinic + home VR get 2.5x the practice dose.

VNS is the strongest chronic-stroke neuromodulation evidence. Medicare covers it. ~30+ US certified centers. Eligible patients: chronic ischemic stroke (≥9 months) with moderate-to-severe upper-limb deficit.

Three large trials (FOCUS n=3,127; AFFINITY n=1,221; EFFECTS n=1,500) definitively showed SSRIs do not improve motor recovery (OR 0.96) and increase fractures, seizures, falls, and hyponatremia. Do not prescribe SSRIs routinely for motor recovery.

Do use them to treat established post-stroke depression — they remove the single biggest barrier to rehab engagement. Escitalopram 10–20 mg or sertraline 50–100 mg are first-line. Avoid paroxetine with DOACs (strongest bleeding signal).

• Daily task-specific practice for life: 30–60 min/day of focused practice on meaningful tasks. Stopping leads to functional decline; continuing produces gains for years.
• Periodic booster intensives: 2–4 weeks of daily high-intensity therapy every 6–12 months breaks plateaus.
• Novelty gates plasticity: Dopamine fires specifically during novel motor learning, not during plateau performance. Continually challenge with unfamiliar activities: music, Argentine tango, language learning, adaptive sports, tai chi, gardening, art.
• Aerobic exercise 3–5x/week remains the single best plasticity booster and chronic-fatigue treatment.
• Sleep: 7–9 hours; treat residual OSA; CBT-I before sleeping pills.
• VNS: Consider if persistent moderate-severe arm weakness ≥6 months post-ischemic stroke.

• BP <130/80 mmHg indefinitely. Home cuff; the TRIDENT trial showed a triple low-dose pill reduced recurrent stroke by 39% in ICH survivors.
• LDL <70 mg/dL. FOURIER: evolocumab reduced stroke by 21%; ODYSSEY: alirocumab reduced stroke by 27%.
• AFib surveillance: Wearable ECG (Apple Watch, KardiaMobile) can detect paroxysmal AF.
• Annual vascular review: Reassess all risk factors, medication adherence, carotid imaging if relevant.

Optimize workarounds for functions that will not return fully: one-handed dressing, weighted utensils, reachers, button hooks, voice-to-text software, communication apps. Orthoses: ankle-foot orthosis for foot drop; FES devices (Bioness L300, WalkAide). Custom hand splints for tone. Home modifications: grab bars, ramps, shower chair, raised toilet seat, stair glide.

Driving: Evaluation by an OT certified in driver rehabilitation; do not drive without clearance, especially if seizures or significant cognitive/visual deficits.

Return to work: Should be staged with neuropsychological evaluation, trial of part-time/modified duties, and workplace accommodations under the ADA.

Many of the setbacks that derail stroke recovery are predictable, and several are preventable or highly treatable if caught early — which is why it helps to know what to watch for rather than being blindsided. The most dangerous early complications are medical: difficulty swallowing (which can let food or liquid enter the lungs and cause pneumonia, the leading medical cause of death after stroke), blood clots in the legs from immobility, infections, and falls. This is a major reason stroke care is best delivered on a dedicated stroke unit, where swallowing is screened before the first sip of water, clot prevention is routine, and mobilization is started carefully.

Over the following weeks and months, a different set of challenges emerges — spasticity (tight, stiff muscles), shoulder pain, fatigue that is far more profound than ordinary tiredness, bladder and bowel changes, and sleep problems. None of these should be silently endured: spasticity responds to stretching, splinting, and targeted botulinum-toxin injections; shoulder pain to proper positioning and therapy; and fatigue to pacing, treating contributors like depression and poor sleep, and graded activity. Seizures occur in a minority and are treatable.

The practical theme is to treat the care team as partners in anticipating these issues. Ask what is being done to prevent clots and pneumonia in the hospital, report new pain or stiffness early, and raise fatigue and sleep as medical issues rather than assuming they are just part of recovery. Getting ahead of complications keeps small problems from becoming the ones that stall progress.

Distinct from depression though heavily overlapping. Workup for reversible causes: OSA, depression, hypothyroidism, anemia, vitamin D/B12 deficiency, medication side effects. Graded aerobic exercise is paradoxically the most effective treatment. Modafinil 200 mg/day reduced fatigue scores significantly in the MIDAS trial. SSRIs do NOT reduce fatigue.

Presents as burning, tingling, shooting, or cold sensations on the side opposite the stroke. Network meta-analysis ranked treatments: lamotrigine strongest (titrate slowly due to rash risk); pregabalin; gabapentin; amitriptyline (first-line per many guidelines); duloxetine off-label. Desensitization techniques help retrain pain processing.

Prevention is paramount: Protect the shoulder from day one; never pull on the affected arm; lap tray for wheelchair; do not move past 90° flexion without scapular rotation; avoid overhead pulleys.

Treatment: NMES/FES is the most effective for subluxation. Kinesio taping leads for functional recovery. Corticosteroid injections lead for pain at rest. ESWT reduces pain and improves motor function.

Dysphagia persists in roughly one-third of survivors. Silent aspiration is the danger. Formal evaluation: VFSS (gold standard) or FEES. Emerging: Expiratory Muscle Strength Training improved swallowing outcomes.

Post-stroke seizures affect ~5–10%. Treatment when they occur: levetiracetam first-line (best side-effect profile; safe with DOACs). Lamotrigine and lacosamide as alternatives.

Stroke recovery is usually pictured as physical — walking, moving an arm, speaking. But the emotional and cognitive aftermath is just as real, often less visible, and frequently under-treated, and addressing it is one of the highest-leverage things you can do for overall recovery. Depression affects roughly a third to forty percent of stroke survivors, and it is not simply “feeling sad about what happened” — stroke itself changes brain chemistry, and post-stroke depression directly worsens physical recovery by sapping the motivation and energy that rehabilitation demands.

The crucial message is that this is treatable, and treating it pays off twice — in quality of life and in better physical recovery. Antidepressants (particularly SSRIs) and talk therapy both help, and screening for depression is recommended at every follow-up visit. Families should watch for withdrawal, loss of interest, sleep and appetite changes, and hopelessness, and raise them with the team rather than assuming they are an inevitable part of stroke.

Cognitive changes — problems with memory, attention, planning, or processing speed — are also common and can be subtle, sometimes mistaken for laziness or simply missed. So can “emotional lability” (sudden crying or laughing that doesn't match the situation), which is a recognized neurological effect of stroke, not a sign of weakness, and is itself treatable. A particular challenge is that some survivors have reduced awareness of their own deficits, which makes a supportive, observant family and a formal neuropsychological assessment especially valuable. Naming these hidden effects, and treating them, is often what allows the physical gains of rehabilitation to translate into a genuinely recovered life.

• Escitalopram 10–20 mg: Head-to-head RCT showed faster onset (~1 week). QT prolongation at >20 mg.
• Sertraline 50–100 mg: Favorable CV profile; fewer interactions.
• Citalopram 10–20 mg: FDA max 20 mg in older adults (QT). Off-label for pathological crying.
• Vortioxetine 10–20 mg: Pro-cognitive effects; reasonable when depression + cognitive complaints overlap.

Avoid paroxetine with DOACs (strongest bleeding signal: ROR 14.12). Prefer escitalopram/citalopram or SNRIs. SNRIs showed no significant bleeding signal.

• CBT: Meta-analysis of 23 RCTs (N=1,972) showed significant depression reduction (SMD -0.83).
• Behavioral activation: Can be delivered by non-specialists after 3–5 days of training. Effective at 6 months.
• Combination SSRI + CBT generally outperforms either alone for moderate-severe depression.
• Aerobic exercise has independent antidepressant benefit.

• Anxiety (20–25%): SSRIs/SNRIs first-line. Buspirone as non-benzo alternative. Avoid chronic benzodiazepines.
• Apathy (~35%): Distinct from depression. SSRIs are NOT effective and may worsen it. Bupropion and methylphenidate have some support. Cholinesterase inhibitors may help with comorbid vascular cognitive impairment.
• Pseudobulbar affect (PBA): Nuedexta (dextromethorphan/quinidine) is FDA-approved. Low-dose SSRIs or nortriptyline off-label.
• Treatment-resistant PSD: Dual-rTMS showed best efficacy in a 2025 network meta-analysis (SUCRA 95.9%).

Post-stroke cognitive impairment affects 30–70% in the first year. Computerized cognitive training (RehaCom, BrainHQ, CogniFit) significantly improved general cognition, attention, and executive function in meta-analysis. Short-term high-frequency training (>3 sessions/week for ≤6 weeks) outperformed long-term low-frequency.

Compensatory strategies (smartphone reminders, structured routines, memory aids) often matter more in daily life than restorative training. Aerobic exercise may be the single most effective cognitive intervention. Treat mood first — depression directly impairs attention, working memory, and executive function.

• Tongxinluo (TISS trial, JAMA 2024, n=2,007): TCM compound showed 65.8% vs 59.1% favorable mRS at 90 days (OR 1.33, p=0.002). No effect in patients >65. Difficult to obtain outside China ($30–50/course).
• Dl-3-n-butylphthalide (NBP): Celery seed derivative; neuroprotection, BBB integrity, angiogenesis. Approved in China only ($150–300/course).
• Buyang Huanwu Decoction: Meta-analysis of 19 RCTs improved NIHSS and Barthel Index combined with Western medicine; methodology often weak ($20–40/month from TCM practitioners).
• Electroacupuncture: Scalp acupuncture + rehab improved FMA by ~10 points in 24 RCTs. Evidence mostly China-only. Use licensed practitioner experienced in stroke; tell about blood thinners ($30–150/session).

• Kaifukuki rehabilitation wards: 85,000 beds nationwide; up to 3 h/day, 7 days/week; mean stay 80 days. Mean FIM gain 23 points; 69% home discharge. Covered by Japanese universal insurance.
• Edaravone Dexborneol: 39.5% higher likelihood of favorable mRS at 90 days vs edaravone alone. Not Western-available.
• Kampo medicine: Ninjin’yoeito, Choto-san — preclinical data on BDNF modulation, neuroinflammation. Small clinical series; no large stroke-specific RCTs.
• Rehab robots (Toyota Welwalk, ReoGo-J): Deployed in 100+ hospitals; limited large RCTs.

• INTERACT3 Care Bundle (Europe): Bundled approach (early BP, glucose, temperature, anticoagulation reversal) significantly improved function and reduced mortality for ICH. Protocol-based, no drug cost.
• ESO 2025 guidelines: First new ICH guideline since 2014; motor rehabilitation dose targets. Open access at eso-stroke.org.
• Cerebrolysin (Russia/EE): Mixed evidence. 14-RCT MA: mean NIHSS improvement +1.39. CARS trial showed benefit at 30 mL IV × 21 days. CASTA did NOT meet primary endpoint. Cochrane: probably no benefit on death. Not FDA-approved ($200–500/course).
• Brain-computer interfaces: 2024 meta-analysis of 25 RCTs showed BCI improves upper-limb function. IpsiHand (FDA-cleared) non-invasive BCI showed benefit in chronic stroke. Commercial systems emerging.
• Stem cell therapy: Legitimate area of research, but experimental and belongs in registered clinical trials. Avoid unregulated cash-pay clinics.

A meta-analysis of 88 randomized controlled trials enrolling 6,431 patients (3,347 intervention, 3,084 control), published in August 2022 in Frontiers in Neurology, examined the effect of acupuncture as an adjunct to standard rehabilitation for post-stroke spasticity.

What the evidence shows: Acupuncture combined with conventional rehabilitation was associated with greater improvements in spasticity (Modified Ashworth Scale), motor function, and activities of daily living compared to conventional rehabilitation alone. The evidence base is notably large — 88 trials is one of the largest compilations for any complementary therapy in stroke.

Important caveats:

• The majority of included trials were conducted in China, where acupuncture is integrated into standard stroke care, raising questions about generalizability and potential publication bias.
• Blinding in acupuncture trials is inherently difficult, which can inflate effect estimates.
• Quality of included studies varied, though the sheer volume of consistent positive signals is notable.

Practical considerations: If you are interested in acupuncture for post-stroke spasticity, seek a licensed acupuncturist experienced in treating stroke patients. Inform them about all blood thinners and medications you take. Acupuncture should be used alongside standard spasticity management (stretching, BoNT-A, rehabilitation), not instead of it.

Source: PMC9428153 — Frontiers in Neurology, August 2022; meta-analysis of 88 RCTs, 6,431 patients

A pilot randomized controlled trial of 201 patients across 7 centers in China, published in March 2023 in Frontiers in Pharmacology, examined EGb 761 (a standardized extract of Ginkgo biloba at 240 mg/day) for post-stroke cognitive impairment.

Important caveats:

• This was an open-label trial (not blinded), which means both patients and researchers knew who received the treatment. This can inflate perceived benefit through placebo and observer bias.
• The sample size (201 patients) is relatively small for a definitive conclusion.
• EGb 761 is a specific standardized extract and is not equivalent to generic ginkgo supplements, which vary widely in composition and quality.

The honest picture: This single pilot trial is promising but preliminary. Post-stroke cognitive impairment affects 30–70% of survivors and has few proven treatments, which makes any positive signal worth noting. However, the open-label design, small sample, and significant drug interaction risks mean this finding needs confirmation in larger, blinded trials before it can be recommended. If your stroke team considers it appropriate in your specific case, EGb 761 specifically (not generic ginkgo) is the formulation studied.

Source: PMC10090660 — Frontiers in Pharmacology, March 2023; pilot RCT, 201 patients, 7 centers in China

dl-3-n-Butylphthalide (NBP) is a synthetic compound derived from celery seed extract. It was approved by China’s National Medical Products Administration (NMPA) for treatment of acute ischemic stroke in 2002 and commercially launched in 2004. NBP is described as the only clinically approved anti-ischemic neuroprotectant in China and is widely used there in both intravenous and oral formulations.

Proposed mechanisms: NBP is reported to act through multiple pathways — improving microcirculation, protecting mitochondrial function, reducing oxidative stress, inhibiting neuroinflammation, supporting blood-brain barrier integrity, and promoting angiogenesis in the ischemic penumbra.

Evidence base:

• Multiple Chinese randomized controlled trials and systematic reviews have evaluated NBP as an adjunct to standard acute stroke treatment.
• A Cochrane-style systematic review and several Chinese meta-analyses report modest improvements in neurological deficit scores (NIHSS) and functional outcomes when NBP is added to conventional care.
• However, the vast majority of trials are single-country (China), many are small, and overall evidence quality is rated as modest by international standards.

Why it is included here: NBP illustrates how stroke treatment varies globally. It is one of the few neuroprotectants to achieve regulatory approval anywhere in the world — a class of drugs that has otherwise failed repeatedly in Western clinical development. Understanding its existence helps patients and families appreciate the breadth of global research, while recognizing that regional approval does not equal universal validation.

Regulatory status: NMPA-approved (China, 2002). Not FDA-approved. Not EMA-approved. Estimated cost in China: $150–300 per treatment course.

Edaravone is a free-radical scavenger first launched in Japan in 2001 for the treatment of acute ischemic stroke within 24 hours of onset. It is used clinically for stroke in Japan, China (where an edaravone-dexborneol combination product has also been developed), India, and parts of Europe.

Proposed mechanism: Edaravone scavenges hydroxyl radicals and peroxynitrite, reducing oxidative damage to neurons, glia, and vascular endothelium during ischemia-reperfusion injury. The edaravone-dexborneol combination adds anti-inflammatory and blood-brain barrier protective properties.

Evidence base:

• Several systematic reviews and meta-analyses (primarily of Japanese and Chinese trials) report modest benefits in neurological deficit improvement and functional outcomes when edaravone is added to standard acute stroke care.
• The edaravone-dexborneol combination showed a 39.5% higher likelihood of favorable mRS at 90 days compared to edaravone alone in a Chinese Phase III trial.
• However, evidence quality is moderate at best — many trials are open-label, and effect sizes are modest. Large multinational confirmatory trials are lacking.

Why it is included here: Edaravone is one of very few neuroprotective agents approved for stroke in any jurisdiction. Like NBP, it demonstrates that different regulatory environments have reached different conclusions about neuroprotection in stroke. For patients researching global treatment approaches, understanding edaravone’s role in Asian stroke care provides important context — while recognizing that Western guidelines do not currently recommend it for stroke.

Regulatory status: Approved for stroke in Japan (2001), China, India, and select markets. FDA-approved for ALS only (not stroke). Not EMA-approved for stroke.

Components: tDCS (or rTMS) + intensive mCIMT or robotic upper-limb training + CPAP for OSA + protected 7–9 h sleep.

Logic: Stimulation lowers cortical firing thresholds; task-specific reps strengthen active synapses via LTP; sleep consolidates gains via spindle-slow oscillation coupling.

When: Subacute (6 weeks–6 months), 3–5 days/week.

Components: 30 min brisk aerobic 5x/week + full MIND adherence + SSRI and/or CBT if depressed + 20–30 min computerized cognitive training 3–5x/week (ideally post-exercise during the BDNF surge).

Logic: Exercise raises BDNF and cerebral blood flow; diet reduces inflammation; mood treatment restores engagement; cognitive training targets specific networks while the brain is primed.

When: All phases; the foundational lifestyle stack.

Components: US-guided BoNT-A every ~12 weeks + intensive OT/PT (3–5x/week) beginning ~10 days post-injection + home VR or mirror therapy 30–45 min daily + caregiver training.

Logic: BoNT-A opens a temporary functional window; rehab fills the window with high-repetition practice; home VR extends dose; trained caregiver ensures carryover.

When: Spasticity-limited subacute or chronic survivors.

Components: Vivistim implantable VNS + 18 in-clinic OT sessions (3x/week × 6 weeks, 300+ pairings/session) + magnet-triggered home self-stimulation + BoNT-A as needed + treated depression.

Logic: VNS time-locks noradrenergic and cholinergic release to motor attempts, amplifying synaptic strengthening — but does nothing without active movements.

When: Chronic ischemic stroke (≥6–9 months) with moderate-severe persistent arm weakness and access to intensive OT.

Stroke is, in a very real sense, a family diagnosis: a spouse, adult child, or parent often becomes a caregiver overnight, with little preparation and enormous responsibility. Caregivers are also at high risk themselves — for depression, anxiety, exhaustion, and their own health problems — and the uncomfortable truth is that a depleted caregiver cannot sustain good care. Protecting your own wellbeing is therefore not selfish; it is part of caring for the survivor.

A few principles help caregivers last the distance. Accept and organize help rather than trying to do everything alone — keep a concrete list of tasks others can take on (meals, rides, sitting with the survivor) so that when people offer, you have an answer ready. Learn the practical skills early (safe transfers, medication schedules, communication strategies for aphasia) from the therapy team while still in the rehab setting, because confidence reduces both risk and stress. Use respite care — short breaks where someone else takes over — before you reach the breaking point, not after. And watch for your own warning signs: persistent exhaustion, hopelessness, resentment, or neglect of your own health are signals to ask for help, not to push harder.

Practically, ask the stroke team or hospital social worker to connect you with caregiver support — support groups (in person or online), the American Stroke Association's resources, and counseling. Plan for the long term, too: address legal and financial matters (power of attorney, benefits, work arrangements) early, while decisions can still be made together. Caregivers who build a support structure and care for themselves not only last longer — the people they care for measurably do better.

• Build a rotation. Even with a primary caregiver, the primary person needs scheduled, protected time off.
• Set up help early. Meal trains, household help, transportation, and respite care are far easier to arrange before a crisis.
• Use respite care. Adult day programs, short-term residential respite, and home aide services exist specifically for this. Using them is good practice, not failure.
• Get hands-on training. Every caregiver should be trained in safe transfers, positioning, swallowing precautions, medication management, and BE-FAST recognition.
• Watch the caregiver’s own health. Caregiver depression, sleep loss, and neglected medical care are common.
• Coordination tools. Free platforms (CaringBridge, Lotsa Helping Hands) let a wider circle of friends and family share updates and sign up for tasks.

If the stroke affected language, the whole family is navigating aphasia — a disorder of language, not intelligence. The person’s thoughts are intact; the channel is damaged.

• Speak in short, direct sentences and give time for a response
• Ask yes/no questions when open ones are hard
• Use gestures, writing, drawing, and pointing freely
• Do not finish sentences or speak for the person unless asked
• The National Aphasia Association (aphasia.org) maintains resources for families

If the survivor has children at home: They need age-appropriate, honest information. Maintain routines; tell the school; let children help in small concrete ways if they want to.

Essential legal documents (complete while capacity is clear):

• Durable power of attorney for healthcare
• Durable power of attorney for finances
• Advance directive / living will
• Will and beneficiary designations (review for currency)
• Access to essential accounts

Household rhythm: A household that treats recovery as a shared, sustainable rhythm — rather than an emergency that never ends — does better on every measure.

Honest hope is not the same as optimism. Optimism says everything will go back to how it was. Honest hope says something sturdier: recovery is real and continues for years; I will do the work that drives it; and my worth and my relationships do not depend on reaching any particular milestone.

Honest hope does the realistic planning — the legal documents, the financial review, the home adjustments — while also pursuing every reasonable avenue of recovery. Both things are true at once.

Grief after stroke is a real and legitimate process. People who navigate this well tend to: let themselves actually mourn rather than rushing to “stay positive”; separate their worth from their function; rebuild around what is still possible; and find purpose — adapted hobbies, relationships, mentoring other survivors, work in some form — which is consistently one of the strongest predictors of psychological recovery.

Not all hospitals are equally equipped for stroke, and the distinction can change outcomes. Stroke centers are certified at levels: a primary stroke center can give clot-busting drugs and provide organized stroke care, while a comprehensive stroke center additionally offers around-the-clock clot-retrieval (thrombectomy), neurosurgery, and neurocritical care for the most complex strokes. For an acute stroke, paramedics often route patients to the most appropriate center based on the suspected severity — one reason to call emergency services rather than self-transport.

For care after the acute phase, it is reasonable — and often valuable — to seek a second opinion or ongoing care at a center with a dedicated stroke program, particularly for complex situations: an unclear cause despite workup, recurrent strokes, a young stroke survivor, or difficult decisions about anticoagulation, carotid surgery, or PFO closure. Asking whether a hospital is a certified stroke center, how many thrombectomies it performs, and whether it has a dedicated stroke unit and rehabilitation program are fair, useful questions. Where you are treated is one of the few parts of stroke care a family can sometimes influence, and it is worth attention.

• What type of stroke did I have — ischemic or hemorrhagic? What was the mechanism (TOAST/ASCOD subtype)?
• If called cryptogenic, have I had prolonged heart-rhythm monitoring to look for atrial fibrillation?
• What is my antithrombotic plan — antiplatelet or anticoagulant, which agent, and for how long?
• What are my individualized targets for blood pressure, LDL, and HbA1c?
• Was I started on a high-intensity statin? When will lipids be rechecked?
• Have I been screened for swallowing safety, depression (PHQ-9), and cognition (MoCA)?
• What rehabilitation setting are you recommending — and why?

• What is my formal therapy prescription — which disciplines, how many minutes/day, how many days/week?
• What are my main functional goals, and how will we measure progress?
• Am I a candidate for CIMT or a modified version?
• Am I a candidate for neuromodulation — tDCS, rTMS, or paired VNS (Vivistim)?
• What can I safely practice at home? How do I avoid injuring the affected shoulder or falling?
• How will spasticity be monitored, and is early BoNT-A appropriate?
• When can the family be trained in transfers, positioning, and swallowing precautions?

• Which of my medications are for preventing another stroke, and what does each do?
• Are there drugs or supplements I should specifically avoid? (St. John’s wort and nattokinase with blood thinners?)
• If I take an antidepressant, is it compatible with my antithrombotic? Is paroxetine being avoided with a DOAC?
• If I need an anti-seizure medication, is it safe with my anticoagulant (levetiracetam or lacosamide)?
• Should supplements be reviewed for interactions before I continue them?

• Given my specific stroke, what is the realistic range of recovery, and what most influences where I land?
• Beyond receiving treatment, what have you seen actually make a difference in long-term recovery?
• What is the most useful thing my family can do to support me?
• When is a second opinion or specialized rehabilitation referral worth pursuing?
• Are there clinical trials I should consider?
• Is there anything you wish more patients and families asked?

• Sudden shortness of breath, chest pain, or coughing up blood — possible pulmonary embolism. Call 911.
• New leg swelling with warmth or tenderness — possible DVT. Contact team same day.
• A new seizure — contact team promptly; if first or prolonged, seek emergency care. No driving without clearance.
• New or rapidly worsening headache — contact team same day; can signal bleeding.
• Fever or signs of infection — contact team; infection transiently raises stroke risk.
• Mood drop lasting >2 weeks — re-screen for depression. Common, treatable, recovery-limiting if missed.
• Any thoughts of self-harm — seek help immediately; call or text 988 in the US.
• Recovery plateaued for several weeks — change the rehab strategy, consider a booster intensive or specialized opinion.
• New medication or supplement being added — ask for an interaction check against the entire regimen.
• Caregiver exhausted or family strained — engage social work and resources. This is a medical issue for the survivor too.

• American Stroke Association (stroke.org) — fact sheets, recovery resources, support-group finder. Stroke Family Warmline: 1-888-478-7653.
• Stroke Onward (strokeonward.org) — emotional and identity side of recovery for survivors and families.
• The Stroke Foundation (thestrokefoundation.org) — Stroke Survivor Fund provides grants for therapy.
• American Stroke Foundation (americanstroke.org) — long-term quality of life programs.
• National Aphasia Association (aphasia.org) — information and support for people with aphasia and families.

• Family Caregiver Alliance (caregiver.org; 800-445-8106) — national caregiver support, education, and navigator service.
• Eldercare Locator (eldercare.acl.gov; 800-677-1116) — connects families to local respite care, adult day programs, and meal services.
• CaringBridge and Lotsa Helping Hands — free platforms for coordinating updates and organizing help.
• Meals on Wheels — community meal delivery; availability varies locally.

• SSDI and SSI — a severe stroke causing lasting disability may qualify; apply at ssa.gov or 800-772-1213. Apply early.
• FMLA — job-protected unpaid leave for a family member providing care.
• Medicare / Medicaid — medicare.gov / 800-633-4227. SHIP offers free, unbiased Medicare counseling.
• Patient Advocate Foundation (800-532-5274), HealthWell Foundation (800-675-8416), PAN Foundation (866-316-7263), NeedyMeds (needymeds.org) — copay and prescription assistance.
• Help Hope Live (helphopelive.org) — community-based medical fundraising.
• 211 / United Way — dial 211 for local programs (transportation, housing, food, utility assistance).

• Adaptive equipment and home modifications: DME may be partially covered by insurance; medical equipment loan closets lend wheelchairs, walkers, shower chairs at no cost. Ask the social worker.
• Transportation: Paratransit and non-emergency medical transportation; Area Agencies on Aging can help arrange rides to therapy.
• Home safety: An OT home-safety evaluation identifies grab bars, ramps, and modifications before discharge.
• Driving: A driver-rehabilitation evaluation determines when and whether driving can safely resume.

Generally avoid post-stroke without explicit approval: high-dose vitamin E (>400 IU); St. John’s wort (dramatically reduces DOAC levels); 5-HTP and L-tryptophan (serotonin syndrome risk with SSRIs); red yeast rice (additive with statins); high-dose green tea extract concentrates.

Statins (atorvastatin, rosuvastatin):

• CoQ10: RECOMMENDED — statins deplete CoQ10; supplementation may reduce myalgia
• Grapefruit / bergamot: AVOID with atorvastatin — raises levels 2–3x (rosuvastatin is safer)
• St. John’s wort: AVOID — reduces atorvastatin levels ~50%
• Red yeast rice: MONITOR/AVOID — contains natural lovastatin; doubles effective statin dose

SSRIs / SNRIs:

• St. John’s wort: CONTRAINDICATED — serotonin syndrome risk
• 5-HTP / L-tryptophan: AVOID — direct serotonin precursors, serotonin syndrome risk
• All Tier 1 supplements: SAFE

SSRI + DOAC bleeding signal: Paroxetine + apixaban showed the strongest bleeding signal (ROR 14.12). Avoid paroxetine with DOACs; prefer escitalopram, citalopram, or an SNRI.

Morning (7:00–8:00 AM) with breakfast:

• Aspirin 81 mg (morning maximizes antithrombotic effect during platelet peak)
• Clopidogrel 75 mg if prescribed (with food)
• Omega-3 2 g (fat-soluble)
• Vitamin D3 2,000–4,000 IU (fat-soluble)
• CoQ10 200 mg (fat-soluble)
• B-complex (energizing — avoid evening)

Mid-morning (10:00 AM) empty stomach:

• NAC 600 mg (better absorbed without food)
• Alpha-lipoic acid 300 mg
• Citicoline 500 mg if using

Lunch (12:00–1:00 PM) with meal:

• Curcumin 500 mg if approved (with fat + piperine)
• Creatine 5 g if using
• Probiotics 30 billion CFU

Afternoon / early evening:

• SSRI if prescribed (consistent daily timing matters most)
• BP medication (evening dosing may improve nocturnal BP dipping — discuss with clinician)

Bedtime (9:00–10:00 PM):

• Atorvastatin 40–80 mg (evening optimal — CYP3A4 activity lower at night; rosuvastatin is not time-sensitive)
• Magnesium glycinate 400 mg (promotes sleep)
• Melatonin 0.5–3 mg if using

Separation rules: Magnesium — 2+ hours from levothyroxine and fluoroquinolones. NAC — 2+ hours from nitroglycerin. Grapefruit — avoid entirely with atorvastatin.

HBOT is heavily marketed to stroke survivors. The FDA has not approved it for stroke recovery. A 2024 meta-analysis (8 RCTs, ~493 patients) found no significant benefit on stroke severity or daily function. Exception: arterial gas embolism-related stroke (established treatment). Insurance does not cover HBOT for stroke. This plan does not recommend it for routine stroke recovery.

Stem cell approaches remain experimental and belong in registered clinical trials. Unregulated clinics sell expensive injections with no credible evidence, no oversight, and real safety risks. The appropriate route is a legitimate clinical trial, not a cash-pay clinic.

Associated with cervical artery dissection in case reports. For someone who has already had a stroke, particularly dissection-related, aggressive neck manipulation should be avoided. Gentler manual therapy and standard PT are safe. Discuss any planned neck treatment with your stroke team.

Three large trials (FOCUS, AFFINITY, EFFECTS; >5,900 patients) disproved routine SSRI use for motor recovery — no functional benefit, and increased fractures, falls, seizures, and hyponatremia. SSRIs remain critically important for treating diagnosed post-stroke depression, but should not be prescribed to people without depression in the hope of improving movement.

• Routine anti-seizure medication for all stroke patients: Not recommended for those without seizures (AHA Class III: No Benefit).
• Multi-supplement “megastacks”: Several common supplements interact dangerously with blood thinners. Single supplements with clear rationale are reasonable; large self-assembled stacks are not.
• “Cure” claims from unverified sources: High-dose IV vitamins, special unproven diets, or non-mainstream approaches should be treated with strong skepticism. Time and hope spent on these is taken from evidence-based strategies.